Catalent, Inc. Announces Pricing of Public Offering of Common Stock to Fund Part of its Acquisition of Cook Pharmica SOMERSET, N.J.

Catalent, Inc. Announces Pricing of Public Offering of Common Stock to Fund Part of its Acquisition of Cook Pharmica

SOMERSET, N.J. September 26, 2017 Catalent, Inc. ( Catalent ) (NYSE:CTLT), the leading global provider of advanced delivery technologies

and development solutions for drugs, biologics, and consumer health products, today announced the pricing of an underwritten public offering (the Offering ) of 6,395,000 shares of its common stock at a price to the public of $39.10 per

share. In connection with the Offering, Catalent has granted the underwriters an option for 30 days to purchase up to an additional 959,250 shares of its common stock sold at the public offering price, less the underwriting discount. Subject to

customary closing conditions, the Offering is expected to settle and close on or about September 29, 2017.

The net proceeds from the Offering will

be approximately $242.2 million after estimated underwriting discounts and commissions payable by Catalent, assuming no exercise by the underwriters of their option. Catalent intends to use the net proceeds of the Offering to fund, in part, the

purchase price of the previously announced pending acquisition (the Acquisition ) of Cook Pharmica LLC ( Cook Pharmica ). Catalent expects to fund the balance of the purchase price and pay related fees and expenses with the net

proceeds from a senior unsecured notes offering (and to the extent all or a portion of the net proceeds from the Offering and/or the notes offering are not available, a senior unsecured bridge loan facility), as well as cash on hand. The Offering is

not contingent on the closing of the Acquisition or any debt financing. If for any reason the Acquisition does not close, Catalent intends to use the net proceeds from the Offering for general corporate purposes.

Morgan Stanley, J.P. Morgan, RBC Capital Markets and BofA Merrill Lynch are acting as underwriters for the Offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of

such shares of common stock or any other security of Catalent in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or

The Offering is being made pursuant to an effective shelf registration statement, including a base prospectus, that has been filed with the

Securities and Exchange Commission (the SEC ) on June 6, 2016 and is available on the SEC website. A preliminary prospectus supplement and the accompanying base prospectus related to the Offering have been filed with the SEC on

September 25, 2017 and are available on the SEC website. Copies of these documents may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; J.P. Morgan

Securities LLC, 383 Madison Avenue, New

York, NY 10179, telephone: 212-834-4533; RBC Capital Markets, LLC, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281, Attention: Syndicate Operations, toll-free:

(877) 822-4089, email: syndicateops2@rbc.com; and BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com. The

registration statement is available on the SEC s website at www.sec.gov under Catalent s name.

FORWARD-LOOKING STATEMENTS

This release contains both historical and forward-looking statements, including concerning the closing of the agreement to purchase Cook Pharmica and the

financing that Catalent intends to obtain to finance the initial purchase price. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities

Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified because they relate to the topics set forth above or by the use of statements that include

phrases such as believe, expect, anticipate, intend, estimate, plan, project, foresee, likely, may, will,

would or other words or phrases with similar meanings. Similarly, statements that describe Catalent s objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of

future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent s expectations and projections. Some of the factors that could cause actual results to

differ include, but are not limited to, the following: antitrust or other regulatory actions that may delay or interfere with the closing of the acquisition or result in other changes to Catalent s business; other unanticipated events that may

prevent a closing of the acquisition or may make it more difficult to realize the anticipated benefits of the transaction; inability to complete the anticipated financing on the anticipated terms, or at all; participation in a highly competitive

market and increased competition may adversely affect the business of Catalent or of Cook Pharmica; demand for Catalent s or Cook Pharmica s offerings which depends in part on their customers research and development and the clinical

and market success of their products; product and other liability risks that could adversely affect the results of operations, financial condition, liquidity, and cash flows of Catalent or Cook Pharmica; failure to comply with existing and future

regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on the business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or

support required; global economic, political, and regulatory risks to the operations of Catalent and Cook Pharmica; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights,

trademarks, and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent and Cook Pharmica manufacture, including active pharmaceutical ingredients,

excipients, purchased components, and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar and other foreign currencies including as a

result of the recent U.K. referendum to exit from the European Union; adverse tax legislation initiatives or challenges to Catalent s tax positions; loss of key personnel; risks generally associated with information systems; inability to

complete any future acquisitions and other transactions that may complement or expand the business of Catalent or divest of non-strategic businesses or assets and Catalent s ability to successfully integrate acquired business and realize

anticipated benefits of such acquisitions; offerings and customers products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and

regulations, which could increase costs and restrict operations; labor and employment laws and regulations; additional cash contributions required to fund Catalent s existing pension plans;

substantial leverage resulting in the limited ability of Catalent to raise additional capital to fund operations and react to changes in the economy or in the industry; exposure to interest rate risk to the extent of Catalent s variable rate

debt and preventing Catalent from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information under the caption Risk Factors in Catalent s preliminary prospectus

supplement filed September 25, 2017 with the SEC and Catalent s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed August 28, 2017 with the SEC. All forward-looking statements speak only as of the date of this

release or as of the date they are made, and Catalent does not undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

Thomas Castellano, 732-537-6325